Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
PurposeTo compare the outcome of patients with Hodgkin lymphoma who received post-transplantation cyclophosphamide-based haploidentical (HAPLO) allogeneic hematopoietic cell transplantation with the outcome of patients who received conventional HLA-matched sibling donor (SIB) and HLA-matched unrelat...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
August 28, 2017
|
| In: |
Journal of clinical oncology
Year: 2017, Volume: 35, Issue: 30, Pages: 3425-3432 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.2017.72.6869 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1200/JCO.2017.72.6869 Verlag, Volltext: http://ascopubs.org/doi/abs/10.1200/JCO.2017.72.6869 
|
| Author Notes: | Carmen Martínez, Jorge Gayoso, Carmen Canals, Hervé Finel, Karl Peggs, Alida Dominietto, Luca Castagna, Boris Afanasyev, Stephen Robinson, Didier Blaise, Paolo Corradini, Maija Itälä-Remes, Arancha Bermúdez, Edouard Forcade, Domenico Russo, Michael Potter, Grant McQuaker, Ibrahim Yakoub-Agha, Christof Scheid, Adrian Bloor, Silvia Montoto, Peter Dreger, Anna Sureda |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1572393769 | ||
| 003 | DE-627 | ||
| 005 | 20230426124303.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180426s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.2017.72.6869 |2 doi | |
| 035 | |a (DE-627)1572393769 | ||
| 035 | |a (DE-576)502393769 | ||
| 035 | |a (DE-599)BSZ502393769 | ||
| 035 | |a (OCoLC)1341007807 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Martínez, Carmen |e VerfasserIn |0 (DE-588)1156721709 |0 (DE-627)1019661607 |0 (DE-576)502392592 |4 aut | |
| 245 | 1 | 0 | |a Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma |b A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation |c Carmen Martínez, Jorge Gayoso, Carmen Canals, Hervé Finel, Karl Peggs, Alida Dominietto, Luca Castagna, Boris Afanasyev, Stephen Robinson, Didier Blaise, Paolo Corradini, Maija Itälä-Remes, Arancha Bermúdez, Edouard Forcade, Domenico Russo, Michael Potter, Grant McQuaker, Ibrahim Yakoub-Agha, Christof Scheid, Adrian Bloor, Silvia Montoto, Peter Dreger, Anna Sureda |
| 264 | 1 | |c August 28, 2017 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 26.04.2018 | ||
| 520 | |a PurposeTo compare the outcome of patients with Hodgkin lymphoma who received post-transplantation cyclophosphamide-based haploidentical (HAPLO) allogeneic hematopoietic cell transplantation with the outcome of patients who received conventional HLA-matched sibling donor (SIB) and HLA-matched unrelated donor (MUD).Patients and MethodsWe retrospectively evaluated 709 adult patients with Hodgkin lymphoma who were registered in the European Society for Blood and Marrow Transplantation database who received HAPLO (n = 98), SIB (n = 338), or MUD (n = 273) transplantation.ResultsMedian follow-up of survivors was 29 months. No differences were observed between groups in the incidence of acute graft-versus-host disease (GVHD). HAPLO was associated with a lower risk of chronic GVHD (26%) compared with MUD (41%; P = .04). Cumulative incidence of nonrelapse mortality at 1 year was 17%, 13%, and 21% in HAPLO, SIB, and MUD, respectively, and corresponding 2-year cumulative incidence of relapse or progression was 39%, 49%, and 32%, respectively. On multivariable analysis, relative to SIB, nonrelapse mortality was similar in HAPLO (P = .26) and higher in MUD (P = .003), and risk of relapse was lower in both HAPLO (P = .047) and MUD (P < .001). Two-year overall survival and progression-free survival were 67% and 43% for HAPLO, 71% and 38% for SIB, and 62% and 45% for MUD, respectively. There were no significant differences in overall survival or progression-free survival between HAPLO and SIB or MUD. The rate of the composite end point of extensive chronic GVHD and relapse-free survival was significantly better for HAPLO (40%) compared with SIB (28%; P = .049) and similar to MUD (38%; P = .59).ConclusionPost-transplantation cyclophosphamide-based HAPLO transplantation results in similar survival outcomes compared with SIB and MUD, which confirms its suitability when no conventional donor is available. Our results also suggest that HAPLO results in a lower risk of chronic GVHD than MUD transplantation. | ||
| 700 | 1 | |a Dreger, Peter |e VerfasserIn |0 (DE-588)1028891881 |0 (DE-627)732699894 |0 (DE-576)376320966 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 35(2017), 30, Seite 3425-3432 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation |
| 773 | 1 | 8 | |g volume:35 |g year:2017 |g number:30 |g pages:3425-3432 |g extent:8 |a Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/JCO.2017.72.6869 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://ascopubs.org/doi/abs/10.1200/JCO.2017.72.6869 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180426 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 1028891881 |a Dreger, Peter |m 1028891881:Dreger, Peter |d 910000 |d 910100 |e 910000PD1028891881 |e 910100PD1028891881 |k 0/910000/ |k 1/910000/910100/ |p 22 | ||
| 999 | |a KXP-PPN1572393769 |e 3007177359 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"August 28, 2017","dateIssuedKey":"2017"}],"recId":"1572393769","type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"doi":["10.1200/JCO.2017.72.6869"],"eki":["1572393769"]},"physDesc":[{"extent":"8 S."}],"relHost":[{"title":[{"title_sort":"Journal of clinical oncology","subtitle":"JCO : an American Society of Clinical Oncology journal","title":"Journal of clinical oncology"}],"part":{"year":"2017","text":"35(2017), 30, Seite 3425-3432","volume":"35","pages":"3425-3432","extent":"8","issue":"30"},"language":["eng"],"pubHistory":["1.1983 -"],"disp":"Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow TransplantationJournal of clinical oncology","physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["313116962"],"zdb":["2005181-5"],"issn":["1527-7755"]},"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"corporate":[{"display":"American Society of Clinical Oncology","role":"isb"}],"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"313116962","origin":[{"dateIssuedKey":"1983","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","dateIssuedDisp":"1983-","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]"}]}],"note":["Gesehen am 26.04.2018"],"name":{"displayForm":["Carmen Martínez, Jorge Gayoso, Carmen Canals, Hervé Finel, Karl Peggs, Alida Dominietto, Luca Castagna, Boris Afanasyev, Stephen Robinson, Didier Blaise, Paolo Corradini, Maija Itälä-Remes, Arancha Bermúdez, Edouard Forcade, Domenico Russo, Michael Potter, Grant McQuaker, Ibrahim Yakoub-Agha, Christof Scheid, Adrian Bloor, Silvia Montoto, Peter Dreger, Anna Sureda"]},"person":[{"family":"Martínez","display":"Martínez, Carmen","given":"Carmen","role":"aut"},{"role":"aut","given":"Peter","display":"Dreger, Peter","family":"Dreger"}],"title":[{"title_sort":"Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma","subtitle":"A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation","title":"Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma"}],"language":["eng"]} | ||
| SRT | |a MARTINEZCAPOSTTRANSP2820 | ||